A Phase 2 interventional study of Dexmedetomidine in Sedation and Pain, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 1 site in United States. Open to participants aged 12 Months to 23 Months. Per ClinicalTrials.gov, last updated 2015-07-24.
Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing dexmedetomidine in Pain — 11 open to participants now, 12 under way, 2 of them phase 3. Dexmedetomidine · Pain.
Among the 64 studies testing dexmedetomidine in Pain, this one is the 60th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2011, is one of 8 in phase 2, and was the 6th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →11 of the 64 studies testing dexmedetomidine in Pain are open now, in 7 countries. Recruiting first, the newest first:
Fatima Memorial Hospital · Sites in Pakistan
Ages 18–60
University Hospital, Montpellier · Sites in France
Ages 1–7
Tanta University · Sites in Egypt
Ages 40–75
Assaf-Harofeh Medical Center · Sites in Israel
Ages 4 wk+
Beni-Suef University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 9 · Phase 4 22
First in 2006; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 70 across the 63 interventional studies. Of the 43 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 64 have an industry lead sponsor. The 10 most frequent:
This study is registered under Hospira, now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.
74 studies in Pain by Pfizer: none open now, none under way, none of them phase 3. Of 72 finished, 34 (47%) have results posted.
Among the 74 studies in Pain by Pfizer, this one is the 68th largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2011, is one of 20 in phase 2, and was the 50th registered.
Pfizer’s Pain studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing dexmedetomidine in Pain, from their registry updates:
Among Pfizer’s 74 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the pharmacokinetic, pharmacodynamic, and safety of dexmedetomidine at 2 different dose levels in pediatric subjects, aged 12 months through \<24 months, administered as an intravenous loading dose followed by continuous infusion for a minimum of 6 hours and up to 24 hours in an intensive care setting.
Phase II, randomized, open-label, single-center, study evaluating the pharmacokinetics and pharmacodynamics of dexmedetomidine in pediatric subjects across two dose levels (Dose Level 1 consists of a 0.7 mcg/kg loading dose immediately followed by a 0.5 mcg/kg/hr maintenance infusion; Dose Level 2 consists of a 1.0 mcg/kg loading dose immediately followed by a 0.75 mcg/kg/hr maintenance infusion). The study population will consist of intubated and mechanically ventilated pediatric subjects who require sedation in an intensive care setting for a minimum of 6 hours but not to exceed 24 hours. Subjects eligible for enrollment are 12 months to \<24 months of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pediatric subjects with neurological conditions that prohibit an evaluation of sedation such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion
Drug: Dexmedetomidine
Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion
Drug: Dexmedetomidine
For sedation according to protocol
Area Under the Plasma Concentration-time Curve (AUC0-∞)
Area under the plasma concentration-time curve of dexmedetomidine at 0 to Infinity hours
Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Observed Peak Plasma Concentration (Cmax)
Maximum observed concentration of dexmedetomidine in plasma
Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Steady State Concentration (Css)
Concentration of dexmedetomidine at steady state in plasma
Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Terminal Elimination Half-life (t1/2)
Terminal elimination half-life of dexmedetomidine. Half-life is the time required for plasma concentration of the drug to decrease by 50%.
Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Time to Reach Maximum Plasma Concentration (Tmax)
Observed time to reach maximum plasma concentration of dexmedetomidine, expressed in hours
Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Weight-Adjusted Plasma Clearance (CLw)
Weight-Adjusted Plasma Clearance of dexmedetomidine after intravenous administration.
Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Plasma Clearance (CL)
Clearance of dexmedetomidine after intravenous administration. Clearance is the rate at which the drug is removed from the plasma after the dose.
Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Volume of Distribution (Vd)
Volume of distribution of dexmedetomidine after intravenous administration. Volume of distribution measures how much the drug spreads through the body after the dose.
Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Weight-Adjusted Volume of Distribution (Vdw)
Weight-Adjusted Volume of distribution of dexmedetomidine after intravenous administration.
Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Average Total Faces, Legs, Activity, Cry, and Consolability (FLACC) Score
FLACC scale is a 5 category observational measure to assess pediatric pain on face, legs, activity, cry and consolability. Responses in each category are scored between 0 to 2 (0 = normal, relaxed to 2 = upset, rigid), for a maximum total score of 10.
Time frame: Prior to loading dose and every hour during the maintenance infusion; within 5 minutes after any fentanyl administration during DEX infusion or every 4 hours in case of continuous fentanyl infusion; within 5 minutes prior and after titration of fentanyl
Absolute Time That Subject is in UMSS Range 2-4 During Treatment Period
The level of sedation will be assessed using the University of Michigan Sedation Scale (UMSS). Score 0 (awake/alert); Score 1 (sleepy/responds appropriately); Score 2 (somnolent/arouses to light stimuli); Score 3 (deep sleep/arouses to deeper physical stimuli); Score 4 (unarousable). The UMSS scores obtained just prior the loading dose (LD) and 5 and 10 minutes during LD; 0, 5, 10, 15, 30, and 60 minutes and thereafter every 4 hours of the maintenance infusion; within 5 minutes of obtaining each pharmacokinetic sample; within 5 minutes prior and after any midazolam rescue during dexmedetomidine infusion period.
Time frame: During the treatment (6 to 24 hours)
Number of Subjects Who Received Rescue Medication for Sedation and Analgesic
Participants who received rescue medication midazolam for sedation and/or fentanyl for analgesic during study drug Infusion
Time frame: During the treatment (6 to 24 hours)
| Milestone | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Started | 2 | 3 |
| Completed | 2 | 3 |
| Not completed | 0 | 0 |
Area under the plasma concentration-time curve of dexmedetomidine at 0 to Infinity hours
| picogram*hour per millilitre | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Area Under the Plasma Concentration-time Curve (AUC0-∞) | 4639.17 ± 4058.1893 | 14203.544 ± 13051.6850 |
Maximum observed concentration of dexmedetomidine in plasma
| picogram per millilitre | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Observed Peak Plasma Concentration (Cmax) | 4499.925 ± 5826.7367 | 11737.387 ± 3549.7923 |
Concentration of dexmedetomidine at steady state in plasma
| picogram per millilitre | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Steady State Concentration (Css) | 752.298 ± 658.0848 | 2303.277 ± 2116.4895 |
Terminal elimination half-life of dexmedetomidine. Half-life is the time required for plasma concentration of the drug to decrease by 50%.
| Hours | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Terminal Elimination Half-life (t1/2) | 1.958 ± 0.3765 | 2.260 ± 1.2205 |
Observed time to reach maximum plasma concentration of dexmedetomidine, expressed in hours
| Hours | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) | 0.083 ± 0.0 | 0.283 ± 0.3464 |
Weight-Adjusted Plasma Clearance of dexmedetomidine after intravenous administration.
| Litre per Hours per Kilogram | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Weight-Adjusted Plasma Clearance (CLw) | 1.292 ± 1.1300 | 0.617 ± 0.3815 |
Clearance of dexmedetomidine after intravenous administration. Clearance is the rate at which the drug is removed from the plasma after the dose.
| Litre per Hour | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Plasma Clearance (CL) | 12.192 ± 9.5770 | 5.836 ± 2.9357 |
Volume of distribution of dexmedetomidine after intravenous administration. Volume of distribution measures how much the drug spreads through the body after the dose.
| Litre | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Volume of Distribution (Vd) | 31.845 ± 20.4351 | 15.780 ± 3.5461 |
Weight-Adjusted Volume of distribution of dexmedetomidine after intravenous administration.
| Litre per Kilogram | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Weight-Adjusted Volume of Distribution (Vdw) | 3.343 ± 2.4910 | 1.590 ± 0.6201 |
FLACC scale is a 5 category observational measure to assess pediatric pain on face, legs, activity, cry and consolability. Responses in each category are scored between 0 to 2 (0 = normal, relaxed to 2 = upset, rigid), for a maximum total score of 10.
| units on a scale | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Average Total Faces, Legs, Activity, Cry, and Consolability (FLACC) Score | 1.575 ± 2.2274 | 3.220 ± 2.1707 |
The level of sedation will be assessed using the University of Michigan Sedation Scale (UMSS). Score 0 (awake/alert); Score 1 (sleepy/responds appropriately); Score 2 (somnolent/arouses to light stimuli); Score 3 (deep sleep/arouses to deeper physical stimuli); Score 4 (unarousable). The UMSS scores obtained just prior the loading dose (LD) and 5 and 10 minutes during LD; 0, 5, 10, 15, 30, and 60 minutes and thereafter every 4 hours of the maintenance infusion; within 5 minutes of obtaining each pharmacokinetic sample; within 5 minutes prior and after any midazolam rescue during dexmedetomidine infusion period.
| Hours | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Absolute Time That Subject is in UMSS Range 2-4 During Treatment Period | 3.6 ± 3.48 | 5.8 ± 0.38 |
Participants who received rescue medication midazolam for sedation and/or fentanyl for analgesic during study drug Infusion
| participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Midazolam for sedation | 1 | 1 |
| Fentanyl for Analgesic | 1 | 2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 | — | 0/2 (0%) | 0/2 (0%) |
| Dose Level 2 | — | 0/3 (0%) | 1/3 (33.3%) |
| Event | Dose Level 1 | Dose Level 2 |
|---|---|---|
| PyrexiaGeneral disorders | 0/2 | 1/3 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 0/2 | 1/3 |
Safety Evaluable Population consisted of all subjects who received any amount of study drug.
| Age, Continuous(years) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Mean | 1.43 ± 0.312 | 1.45 ± 0.274 | 1.44 ± 0.249 |
| Sex: Female, Male(Participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 3 | 4 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
The record gives a start of Jun 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 3 years 11 months after primary completion. A results delay was requested in Sep 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Hospira, now a wholly owned subsidiary of Pfizer →